Cover PCR/multiplex NAATs for symptomatic vaginitis

PCR and multiplex amplified-probe and NAAT tests (including listed CPT codes such as 0353U, 0352U, 81513, 81514, 87481, 87511, 87660, 87661) are considered medically necessary and covered when the patient has symptoms of vaginitis or specified risk factors (see coverage criteria).

• Covered for symptomatic women or when selection criteria/risk factors are present.
• Examples of covered assays include BD MAX vaginitis panel, Aptima BV, NuSwab VG, OneSwab BV Panel, SureSwab BV.

No explicit prior authorization statements for custom PCR panels

The policy text does not state plan-level prior authorization requirements for the described tests; custom multi-organism PCR panels (e.g., Bridge Diagnostics OpenArray) are described as investigational but payer prior authorization rules are not specified here.

• Bridge Diagnostics OpenArray vaginal pathogen panel is listed in the document as a custom assay (see investigational description).
• This bulletin does not enumerate payer-specific prior authorization steps for custom panels.

Follow plan-specific prior authorization processes

Consult your plan-specific prior authorization processes — Clinical Policy Bulletins are intended to assist in administering benefits but do not themselves grant coverage or describe payer authorization workflows.

• Clinical Policy Bulletins are descriptive and may be updated; check member contract and payer prior authorization portal for requirements.

Start with microscopy/pH/amine testing; use molecular tests as indicated

Use office microscopy (Amsel criteria, wet mount), vaginal pH and amine testing as established initial diagnostic approaches; DNA probe or PCR testing may be used as an alternative or when microscopy is inconclusive or higher sensitivity is desired.

• Amsel's criteria (≥3 of 4) and Gram stain/Nugent remain reference methods; molecular assays are supported for symptomatic patients.
• DNA probe tests (e.g., Affirm VP III) provide higher sensitivity compared with clinician microscopy.

Step therapy not specified — molecular testing may follow/replace in‑clinic tests

No formal step-therapy sequence is specified in this bulletin; molecular testing may follow or replace clinician in‑clinic testing for symptomatic patients per guideline context.

• CDC guidance: BV NAATs should be used among symptomatic women only.
• Routine stepwise authorization requirements are not described in this excerpt.

Document clinical indication when ordering molecular tests

When ordering nucleic acid, DNA probe, or PCR testing, document the patient's clinical symptoms of vaginitis or the presence of listed risk factors to demonstrate that selection criteria for covered CPT codes are met.

• Document symptoms such as vaginal discharge, odor, or itch and any applicable risk factors (e.g., new/multiple partners, history of STDs).
• Link documentation to the specific test ordered and the covered CPT/ICD-10 code rationale.

Document diagnostic method (Amsel, Nugent, Hay/Ison) used

When using referenced diagnostic methods, document the specific method employed (e.g., Amsel criteria, Gram stain with Nugent scoring, Hay/Ison grading) in the medical record.

• Record Amsel findings (which require ≥3 of 4 criteria for BV diagnosis) or the Nugent/Gram-stain result where performed.
• Note that guidelines identify Gram stain as gold standard and recommend Amsel if Gram stain unavailable.

Provider responsible for medical advice; CPBs are guidance only

Treating providers are solely responsible for medical advice and treatment; Clinical Policy Bulletins provide general descriptions of plan benefits and do not substitute for clinical judgment.

• Use the bulletin as a guide for benefit administration, but base clinical decisions on provider judgment and current clinical guidance.

Pap smear for Candida vulvovaginitis is investigational — denial risk

Use of a Pap smear (cervical cytology) for diagnosis of Candida vulvovaginitis is considered experimental/investigational and is not supported for this indication.

• Pap tests have low sensitivity for BV and cervical Pap tests have no clinical utility for BV diagnosis per CDC.

Routine screening in asymptomatic women not covered — denial risk

Routine cytopathology/screening tests for asymptomatic women (codes such as G0123–G0148, P3000–P3001, Q0091 and related cytopathology codes) are not covered for the indications listed and may be denied when used for screening asymptomatic patients.

• Routine screening for Candida and Gardnerella in asymptomatic women is considered experimental/investigational and not covered.
• Cytopathology screening codes are listed in the CPB as not covered for the specified indications.

Limit NAAT/PCR use to symptomatic patients — potential denial risk if used for screening

NAATs and PCR tests for bacterial vaginosis are recommended for symptomatic women only; use among asymptomatic women has undefined accuracy and may be challenged during claims review.

• CDC: BV NAATs should be used among symptomatic women only (e.g., discharge, odor, itch).
• Clinical utility of PCR in asymptomatic populations is uncertain and may not meet coverage criteria.

Policy scope disclaimer — CPBs guide benefits but are not coverage guarantees

Clinical Policy Bulletins are developed to assist in administering plan benefits, do not constitute offers of coverage or a contract, and the bulletin may be updated; failure to follow current policy may affect claim adjudication.

• Check member contract and payer resources for definitive coverage and authorization rules.